Biosimilar Newsletter Archive

1. 05.07.26 -- The Business Case For Continuous Manufacturing In Biologics 5/7/2026
   05/07/26 Biosimilar Development Newsletter
2. 04.30.26 -- Quantifying Single-Use Waste Produced During mAb Manufacture 4/30/2026
   04/30/26 Biosimilar Development Newsletter
3. 04.16.26 -- Innovation That's Redefining Aseptic Filling 4/16/2026
   04/16/26 Biosimilar Development Newsletter
4. 04.16.26 -- How Biopharma Continues To Grapple With Annex 1 4/16/2026
   04/16/26
5. 04.09.26 -- Trends In FDA 2025 Warning Letters 4/9/2026
   04/09/26
6. 04.02.26 -- The Hidden Engineering Behind Successful Upstream Bioprocessing 4/2/2026
   04/02/26 Biosimilar Development Newsletter
7. 03.26.26 -- A simple, helpful look at PUPSIT implementation. 3/26/2026

   03/26/26 Biosimilar Development Newsletter

8. 03.26.26 -- A Practical Look At Modern Downstream Processing For Biologics 3/26/2026
   03/26/26 Biosimilar Development Newsletter
9. 03.24.26 -- Stop Engineering Cells. Start Engineering Glycans. 3/24/2026

   03/24/26 Biosimilar Development Newsletter

10. 03.19.26 -- Struggling with mAb aggregation and other impurities? 3/19/2026

    03/19/26 Biosimilar Development Newsletter